30388

30388
U.S. Food and Drug Administration (FDA). Drug approval package. FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. 2015 [cited: 2020-06-25]. https://www.fda.gov/media/93815/download
Einstellungen
30388
nein
Kategorisierung
Sitemap
nein
Wird geladen
zuletzt verändert: 17.03.2021 | 21:33 Uhr